USO DE ANTICUERPOS MONOCLONALES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER: AVANCES Y DESAFÍOS
DOI:
https://doi.org/10.56238/levv17n60-045Palabras clave:
Enfermedad de Alzheimer, Anticuerpos Monoclonales, Beta-amiloide, Neurodegeneración, TratamientoResumen
La enfermedad de Alzheimer es una enfermedad neurodegenerativa progresiva y la principal causa de demencia a nivel mundial, caracterizada por deterioro cognitivo, pérdida de memoria y cambios en el comportamiento. En las últimas décadas, los avances en la comprensión de la fisiopatología de la enfermedad, especialmente en lo relacionado con la acumulación de péptidos beta-amiloides y proteína tau, han impulsado el desarrollo de nuevas estrategias terapéuticas. En este contexto, los anticuerpos monoclonales se presentan como una alternativa prometedora, con el potencial de reducir las placas amiloides y ralentizar la progresión de la enfermedad. Por lo tanto, este estudio tuvo como objetivo analizar los avances y desafíos del uso de anticuerpos monoclonales en el tratamiento de la enfermedad de Alzheimer. Se trata de una revisión bibliográfica integradora, realizada en las bases de datos Medline, LILACS y Science Direct. Se utilizaron descriptores controlados de DeCS y MeSH, combinados mediante el operador booleano AND: "Enfermedad de Alzheimer", "Anticuerpos monoclonales" y "Péptidos beta-amiloides". Se incluyeron artículos publicados entre 2020 y 2025 en portugués, inglés y español. Se espera que los resultados pongan de relieve los beneficios terapéuticos y los desafíos asociados al uso de estos medicamentos, incluyendo la eficacia clínica, la seguridad, los efectos adversos, los costos y el acceso al tratamiento. De esta manera, la investigación contribuye a ampliar el conocimiento científico y a impulsar futuras investigaciones sobre terapias innovadoras para la enfermedad de Alzheimer.
Descargas
Referencias
ANDREWS, S. J.;et al. The complex genetic architecture of Alzheimer's disease: novel insights and future directions. EBioMedicine, v. 90, p. 104511, 2023. DOI: https://doi.org/10.1016/j.ebiom.2023.104511 . Disponível em: https://pubmed.ncbi.nlm.nih.gov/36907103/ . Acesso em: 5 out. 2025.
ANDREWS, Samantha J.; GOATE, Alison. Molecular mechanisms of Alzheimer’s disease. Annual Review of Genomics and Human Genetics, v. 24, p. 47-72, 2023.
ARAI, Heii et al. Safety of switching from lecanemab to donanemab in patients with Alzheimer’s disease. Journal of Alzheimer’s Disease, v. 107, n. 2, p. 494-495, 2025.
BELLENGUEZ, C. et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, v. 54, n. 4, p. 412–436, 2022. DOI: https://doi.org/10.1038/s41588-022-01024-z . Disponível em: https://pubmed.ncbi.nlm.nih.gov/35379992/ . Acesso em: 5 out. 2025.
BELLENGUEZ, Celine et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nature Genetics, v. 54, p. 412-436, 2022.
CUMMING, J.; et al Alzheimer's disease drug development pipeline: 2024. Alzheimer's & Dementia (New York, N. Y.), v. 10, n. 2, e12465, 2024. DOI: https://doi.org/10.1002/trc2.12465 . Disponível em: https://pubmed.ncbi.nlm.nih.gov/38659717/. Acesso em: 5 out. 2025.
CUMMINGS, Jeffrey et al. Aducanumab: appropriate use recommendations. Journal of Prevention of Alzheimer’s Disease, v. 8, p. 398-410, 2021.
CUMMINGS, Jeffrey et al. Alzheimer’s disease drug development pipeline: 2024. Alzheimer's & Dementia, v. 20, n. 2, p. 1-21, 2024. DOI: https://doi.org/10.1002/alz.13811.
DE SOUSA, M. N. A.; BEZERR, A. L. D.; DO EGYPTO, I. A. S. Trilhando o caminho do conhecimento: o método de revisão integrativa para análise e síntese da literatura científica. Observatório de la Economía Latinoamericana, [S. l.], v. 21, n. 10, p. 18448–18483, 2023. DOI: 10.55905/oelv21n10-212. Disponível em: https://ojs.observatoriolatinoamericano.com/ojs/index.php/olel/article/view/1902. Acesso em: 5 out. 2025.
FDA - Food and Drug Administration. FDA aprova tratamento para adultos com doença de Alzheimer. Disponível em: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease. Acesso em: 13 set. 2024.
GAO, S. et al. Interpretation of 10 years of Alzheimer's disease genetic findings in the perspective of statistical heterogeneity. Briefings in Bioinformatics, v. 25, n. 3, bbae140, 2024. DOI: https://doi.org/10.1093/bib/bbae140. Disponível em: https://pubmed.ncbi.nlm.nih.gov/38711368/ . Acesso em: 5 out. 2025.
GAO, Yifan et al. Advances in monoclonal antibody therapies for Alzheimer’s disease. Frontiers in Neuroscience, v. 18, 2024. DOI: https://doi.org/10.3389/fnins.2024.1354010.
HAEBERLEIN, S. Budd et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. Journal of Prevention of Alzheimer’s Disease, v. 9, n. 2, p. 197-210, 2022.
HASSUNUMA, R. M. et al. Revisão integrativa e redação de artigo científico: uma proposta metodológica em 10 passos. Revista Multidisciplinar em Educação e Meio Ambiente, v. 5, n. 3, 2024. DOI: https://doi.org/10.51161/integrar/rems/4275 . Disponível em: https://www.editoraintegrar.com.br/publish/index.php/rema/article/view/4275. Acesso em: 5 out. 2025.
KAMONDI, A.; et al. A. Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums. Nature Reviews Neurology, v. 20, n. 3, p. 162–182, 2024. DOI: https://doi.org/10.1038/s41582-024-00932-4. Disponível em: https://pubmed.ncbi.nlm.nih.gov/38356056/. Acesso em: 5 out. 2025.
KAMONDI, Anna et al. Neurological comorbidities in Alzheimer’s disease and their clinical implications. Neurological Sciences, v. 45, p. 1153-1165, 2024.
KNOPMAN, David S.; JONES, David T.; GREICIUS, Michael D. Failure to demonstrate efficacy of aducanumab: analysis of the EMERGE and ENGAGE trials. Neurology, v. 97, n. 7, p. 329-337, 2021.
MINTUN, Mark A. et al. Donanemab in early Alzheimer disease. New England Journal of Medicine, v. 384, p. 1691-1704, 2021.
MINTUN, Mark A. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA, v. 330, n. 6, p. 512-527, 2023.
NITRINI, R. Doença de Alzheimer: parte 2 – o presente. Arquivos de Neuro-Psiquiatria, v. 82, 2024. DOI: 10.1055/s-0044-1791755. Disponível em: https://www.thieme-connect.de/products/ejournals/html/10.1055/s-0044-1791755. Acesso em: 5 out. 2025.
NITRINI, Ricardo et al. Revised criteria for diagnosis and staging of Alzheimer’s disease. Arquivos de Neuro-Psiquiatria, v. 82, n. 3, p. 215-224, 2024.
SALLOWAY, Stephen et al. TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early symptomatic Alzheimer’s disease. Alzheimer's & Dementia, 2025.
SELKOE, Dennis J.; HARDY, John. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine, v. 8, p. 595-608, 2021.
SIMUFRANIL, H.; ANDERSEN, O.; KARRAN, E. Targeting amyloid-β in Alzheimer’s disease: therapeutic progress and challenges. Nature Reviews Neurology, v. 17, p. 557-575, 2021.
SNIDER, H. Literature review as a research methodology: an overview and guidelines. Journal of Business Research, v. 104, p. 333–339, nov. 2019. Disponível em: https://www.sciencedirect.com/science/article/pii/S0148296319304564 . Acesso em: 05 out. 2025.
SOUZA, M. T.; SILVA, M. D.; CARVALHO, R. Integrative review: what is it? How to do it? Einstein, São Paulo, v. 8, n. 1, p. 102–106, 2010. Disponível em: https://www.scielo.br/j/eins/a/ZQTBkVJZqcWrTT34cXLjtBx/?lang=en. Acesso em: 5 out. 2025.
SWANSON, Christian J. et al. A randomized, double-blind, phase 3 trial of lecanemab in early Alzheimer’s disease. New England Journal of Medicine, v. 388, p. 9-21, 2023.
VAN DYCK, Christopher H. et al. Lecanemab in early Alzheimer’s disease. New England Journal of Medicine, v. 388, p. 9-21, 2023.
YAGHMAEI, E. et al. Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer's disease patients. Communications Medicine, v. 4, n. 1, p. 99, 2024. DOI: https://doi.org/10.1038/s43856-024-00527-6
YAGHMAEI, Shirin et al. Monoclonal antibody therapies targeting amyloid-β in Alzheimer’s disease: clinical perspectives. Biomedicine & Pharmacotherapy, v. 171, 2024.
YANG, Chao et al. Efficacy and safety of anti-amyloid beta monoclonal antibodies in Alzheimer’s disease: a systematic review. Journal of Alzheimer’s Disease, v. 93, p. 789-804, 2024.
